Imagine waking up every day with a condition that makes your body attack itself. That's the reality for many people with systemic lupus erythematosus (SLE), a complex autoimmune disease that can cause fatigue, joint pain, and serious organ problems. Even with standard treatments, some patients still suffer from debilitating symptoms. That's where anifrolumab comes in. This new subcutaneous treatment is being tested in a large study to see if it can provide better relief for those with moderate to severe lupus who aren't responding well to current therapies. In this study, around 360 participants will receive either anifrolumab or a placebo, and researchers will closely monitor their responses. If anifrolumab proves effective, it could offer hope to countless individuals struggling to manage their lupus. However, it's important to remember that not every treatment works for everyone, and we still need to see the final results of this study. For now, this research represents a step forward in the fight against lupus, and it could pave the way for more effective treatments in the future.
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary OutcomeCould a New Treatment Offer Hope for Patients with Lupus?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Monitor for upcoming BICLA response data on anifrolumab in SLE treatment.
This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study investigates the efficacy and safety of subcutaneous anifrolumab in adult patients with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) who are already receiving standard of care (SOC) treatments. The study enrolled 367 participants aged 18 to 70 years, who were randomized in a 1:1 ratio to receive either anifrolumab or placebo. The primary endpoint is the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response. While the trial is active and not recruiting, specific statistical outcomes such as hazard ratios, odds ratios, relative risks, p-values, or confidence intervals have not yet been reported. Secondary endpoints and safety data, including adverse events, will be crucial to understanding the full clinical implications of anifrolumab in this patient population. The trial is sponsored by AstraZeneca and is expected to complete its primary phase by August 2025.
What this means for you:
A new treatment for lupus could bring hope to those struggling with uncontrolled symptoms and improve their quality of life. More on Systemic Lupus Erythematosus
Subcutaneous anifrolumab improves BICLA response by 15.5% in moderate to severe SLE
Anifrolumab injection improves lupus outcomes in trial
This phase 3 RCT in 367 adults with moderate to severe SLE found that subcutaneous anifrolumab 120 mg weekly plus standard therapy improved …
A weekly injection of anifrolumab helped more people with lupus achieve disease control than placebo, a phase 3 trial shows.
SLE-DAS Responder Index shows 34% response rate in systemic lupus erythematosus trials
New Lupus Measurement Tool Predicts Patient Quality of Life Improvements
This post-hoc analysis of three randomized trials in 438 patients with systemic lupus erythematosus found that 34.0% achieved SLE-DAS Respon…
• A new lupus activity score tracks real patient improvements better • Helps people in clinical trials get effective treatments faster • Sti…
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
Belimumab and anifrolumab show different strengths for lupus patients
This meta-analysis compared belimumab and anifrolumab using indirect evidence from randomized controlled trials involving 4332 patients with…
A new analysis compares two lupus drugs. Belimumab worked better for overall disease control, while anifrolumab helped lower steroid doses a…
View Original Abstract ↓
Status: ACTIVE_NOT_RECRUITING | Phase: PHASE3
Condition(s): Systemic Lupus Erythematosus
Intervention(s): Medi-546 (DRUG), Placebo (DRUG)
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
Detailed: This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of a subcutaneous treatment regimen of anifrolumab versus placebo in participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. Participants must be taking either 1 or any combination of the following: oral glucocorticoids, antimalarial, and/or immunosuppressants. The study will be performed in adult participants of 18 to 70 years of age.
Approximately 360 participants receiving SOC treatment will be randomised in a 1:1 ratio to receive a fixed subcutaneous dose of anifrolumab or placebo administered once weekly via an accessorized prefilled syringe and with the
Primary Outcome(s): British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Enrollment: 367 (ACTUAL)
Lead Sponsor: AstraZeneca
Start: 2021-06-08 | Primary Completion: 2025-08-22
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis
Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients
Related in Rheumatology
Long-term personalized exercise therapy shows potential cost-effectiveness for patients with axial spondyloarthritis
Personalized exercise therapy shows promise for axial spondyloarthritis patients
Researchers evaluated the cost-utility of long-term, personalized exercise therapy compared to usual care in patients with axial spondyloart…
New research looks at whether personalized, long-term exercise programs are a cost-effective way to manage severe axial spondyloarthritis.
EmiratesMEDs competency framework establishes 9 thematic roles and 14 EPAs for UAE medical education
New UAE framework sets 85 competencies for medical graduates
This guideline outlines the EmiratesMEDs competency framework designed to harmonize undergraduate medical education in the United Arab Emira…
A national competency framework for UAE medical graduates defines 85 skills and 14 clinical tasks to standardize education.
Esketamine significantly reduces postoperative anxiety (SMD -1.23) and depressive symptoms (SMD -0.92) in adult patients
Esketamine reduces anxiety and depression after surgery
This meta-analysis of 1,312 adults undergoing general anesthesia found that esketamine significantly reduced both anxiety and depression pos…
New data shows esketamine can significantly lower feelings of anxiety and depression in adults following surgery.
Machine learning and postoperative indicators improve AUC for predicting anastomotic leak in gastric cancer surgery
Machine Learning Models May Better Predict Gastric Cancer Complications
This systematic review and meta-analysis of 18 studies involving 15,783 patients evaluated risk prediction models for anastomotic leak. The …
New analysis shows machine learning models may offer better accuracy in predicting surgical complications for patients with gastric cancer.
From Other Specialties
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…
HIFU combined with ethanol ablation or GnRH-a improves intraoperative outcomes for adenomyosis treatment
HIFU Combined With Medication Shows Better Results for Adenomyosis
This network meta-analysis of 1,685 patients evaluated HIFU combined with various medications compared to HIFU alone for adenomyosis. The an…
Combining high-intensity focused ultrasound (HIFU) with specific medications may improve treatment outcomes for people with adenomyosis.
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …